BR112019025612A2 - Métodos de manipular carga de superfície para a produção de anticorpos biespecíficos - Google Patents

Métodos de manipular carga de superfície para a produção de anticorpos biespecíficos

Info

Publication number
BR112019025612A2
BR112019025612A2 BR112019025612-1A BR112019025612A BR112019025612A2 BR 112019025612 A2 BR112019025612 A2 BR 112019025612A2 BR 112019025612 A BR112019025612 A BR 112019025612A BR 112019025612 A2 BR112019025612 A2 BR 112019025612A2
Authority
BR
Brazil
Prior art keywords
methods
antibody
production
surface load
heavy chain
Prior art date
Application number
BR112019025612-1A
Other languages
English (en)
Inventor
Nesspor Thomas
Original Assignee
Janssen Biotech, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Biotech, Inc. filed Critical Janssen Biotech, Inc.
Publication of BR112019025612A2 publication Critical patent/BR112019025612A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2848—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta3-subunit-containing molecules, e.g. CD41, CD51, CD61
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Abstract

a presente invenção refere-se a métodos de modificar o ponto isoelétrico de um anticorpo. o método inclui fornecer um anticorpo que compreende um primeiro polipeptídeo que compreende uma região variável de cadeia pesada e um segundo polipeptídeo que compreende a região variável de cadeia pesada e substituir, em ao menos um dentre o primeiro e o segundo polipeptídeos do anticorpo, um ou mais resíduos de aminoácido da região variável da cadeia pesada (vh) nas posições 7, 9, 11, 14, 41, 70, 74, 82a, 84 e 113, de acordo com o sistema de numeração de kabat, em que a substituição aumenta ou diminui o ponto isoelétrico do anticorpo.
BR112019025612-1A 2017-06-05 2018-06-04 Métodos de manipular carga de superfície para a produção de anticorpos biespecíficos BR112019025612A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762515297P 2017-06-05 2017-06-05
US62/515,297 2017-06-05
PCT/IB2018/053996 WO2018224950A1 (en) 2017-06-05 2018-06-04 Methods of engineering surface charge for bispecific antibody production

Publications (1)

Publication Number Publication Date
BR112019025612A2 true BR112019025612A2 (pt) 2020-06-16

Family

ID=64566522

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112019025612-1A BR112019025612A2 (pt) 2017-06-05 2018-06-04 Métodos de manipular carga de superfície para a produção de anticorpos biespecíficos

Country Status (10)

Country Link
US (2) US11192951B2 (pt)
EP (1) EP3634994A4 (pt)
JP (1) JP7268011B2 (pt)
KR (1) KR20240056666A (pt)
CN (1) CN110959012A (pt)
AU (1) AU2018279278A1 (pt)
BR (1) BR112019025612A2 (pt)
CA (1) CA3065447A1 (pt)
MX (1) MX2019014572A (pt)
WO (1) WO2018224950A1 (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020167122A1 (en) * 2019-02-14 2020-08-20 Merus N.V. Producing compositions comprising two or more antibodies.
WO2021194839A1 (en) * 2020-03-25 2021-09-30 Eli Lilly And Company Multispecific binding proteins and methods of developing the same

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US7879328B2 (en) * 2000-06-16 2011-02-01 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to B lymphocyte stimulator
US8188231B2 (en) 2002-09-27 2012-05-29 Xencor, Inc. Optimized FC variants
WO2006028936A2 (en) 2004-09-02 2006-03-16 Genentech, Inc. Heteromultimeric molecules
US8802820B2 (en) 2004-11-12 2014-08-12 Xencor, Inc. Fc variants with altered binding to FcRn
WO2006124269A2 (en) 2005-05-16 2006-11-23 Amgen Fremont Inc. Human monoclonal antibodies that bind to very late antigen-1 for the treatment of inflammation and other disorders
EP1931709B1 (en) 2005-10-03 2016-12-07 Xencor, Inc. Fc variants with optimized fc receptor binding properties
US9670269B2 (en) * 2006-03-31 2017-06-06 Chugai Seiyaku Kabushiki Kaisha Methods of modifying antibodies for purification of bispecific antibodies
EP3689912A1 (en) 2007-09-26 2020-08-05 Chugai Seiyaku Kabushiki Kaisha Method of modifying isoelectric point of antibody via amino acid substitution in cdr
EP2318436A4 (en) 2008-08-14 2012-12-19 Cephalon Australia Pty Ltd ANTIBODIES OF DIFFERENT DOMAINS
WO2010131733A1 (ja) * 2009-05-15 2010-11-18 中外製薬株式会社 抗axl抗体
GB201003701D0 (en) 2010-03-05 2010-04-21 Cilian Ag System for the expression of a protein
SG184427A1 (en) 2010-04-20 2012-11-29 Genmab As Heterodimeric antibody fc-containing proteins and methods for production thereof
WO2014055897A2 (en) * 2012-10-04 2014-04-10 Dana-Farber Cancer Institute, Inc. Human monoclonal anti-pd-l1 antibodies and methods of use
TWI693073B (zh) * 2012-12-21 2020-05-11 日商中外製藥股份有限公司 對ｇｐｃ３標的治療劑療法為有效之患者投與的ｇｐｃ３標的治療劑
US9605084B2 (en) 2013-03-15 2017-03-28 Xencor, Inc. Heterodimeric proteins
AU2014244444A1 (en) * 2013-03-14 2015-09-24 Amgen Inc. CHRDL-1 antigen binding proteins and methods of treatment
TW202248212A (zh) * 2015-02-05 2022-12-16 日商中外製藥股份有限公司 包含離子濃度依賴之抗原結合域的抗體、Fc區變體、IL-8結合抗體與其用途
CA2977321A1 (en) 2015-04-29 2016-11-03 Institute For Research In Biomedicine Ultra-potent neutralization of cytokines by multispecific antibodies and uses thereof
US10113003B2 (en) 2015-06-23 2018-10-30 Innate Pharma Multispecific NK engager proteins
PE20181336A1 (es) * 2015-09-18 2018-08-21 Chugai Pharmaceutical Co Ltd Anticuerpos que se unen a interleucina 8 (il-8) y sus usos
TWI748962B (zh) * 2015-09-23 2021-12-11 美商建南德克公司 抗ｖｅｇｆ抗體之最佳化變異體
US20210198368A1 (en) * 2016-01-21 2021-07-01 Novartis Ag Multispecific molecules targeting cll-1

Also Published As

Publication number Publication date
RU2019143638A3 (pt) 2022-02-10
CA3065447A1 (en) 2018-12-13
EP3634994A4 (en) 2021-06-30
AU2018279278A1 (en) 2019-12-19
US11192951B2 (en) 2021-12-07
US20190031764A1 (en) 2019-01-31
KR20240056666A (ko) 2024-04-30
JP2020522573A (ja) 2020-07-30
KR20200014385A (ko) 2020-02-10
MX2019014572A (es) 2020-07-29
WO2018224950A1 (en) 2018-12-13
US20220169741A1 (en) 2022-06-02
CN110959012A (zh) 2020-04-03
JP7268011B2 (ja) 2023-05-02
RU2019143638A (ru) 2021-07-09
EP3634994A1 (en) 2020-04-15

Similar Documents

Publication Publication Date Title
AR123115A1 (es) Composiciones y métodos para la degradación selectiva de proteínas
BR112018068216A2 (pt) método e dispositivo para o manejo de mercadorias movidas uma após a outra em pelo menos uma fila
BR112013008407A2 (pt) antígenos de clostridium difficile
WO2016071376A3 (en) Fc-region variants with modified fcrn-binding and methods of use
BR112016016411A2 (pt) VARIANTES DE REGIÕES-"Fc" COM PROPRIEDADES DE LIGAÇÃO DE "FcRn" MODIFICADAS
PH12019502276A1 (en) Self-assembling protein nanostructures displaying paramyxovirus and/or pneumovirus f proteins and their use
BR112019025612A2 (pt) Métodos de manipular carga de superfície para a produção de anticorpos biespecíficos
BR112018071107A2 (pt) composições e métodos para a detecção de proteínas da célula hospedeira
BR112014024751A2 (pt) antígenos de clostridium difficile
BR112019003785A2 (pt) tabaco resistente a vírus e método de melhoramento para o mesmo
BR112016026842A2 (pt) preparação compreendendo fator viii e peptídeos de fator de von willebrand
BR112017025728A2 (pt) fragmentos mutantes da proteína ras
BR112018072140A2 (pt) anticorpos anti-basigin humanizados e uso dos mesmos
EA201792329A1 (ru) Способ мономеризации рекомбинантных молекул антител
EA201891990A1 (ru) Слитые белки на основе рекомбинантного фоллистатина и fc-фрагмента и их применение в лечении мышечной дистрофии дюшенна
BR112016014913A8 (pt) anticorpo, ou um fragmento de ligação ao antígeno do mesmo, conjugado, ácido nucléico, vetor, célula hospedeira, composição farmacêutica, método de preparo de uma cadeia leve de um anticorpo ou fragmento de ligação ao antígeno e método de preparo de um conjugado
BR112017017609A2 (pt) proteína de fusão fc, e, composição farmacêutica.
BR112016015867A2 (pt) anticorpos de elevada afinidade e resistentes à agregação com base nas regiões variáveis vl e no derivado vhh
WO2021050009A3 (en) Composition of renaturation buffer solution for dimeric proteins and method of renaturation dimeric proteins using the composition thereof
BR112018074988A2 (pt) processo e dispositivo para manuseio de mercadorias em peças dispostas uma atrás da outra em pelo menos uma fila
CL2017000200A1 (es) Célula huésped mejorada para producir proteinas
BR112018009851A2 (pt) polipeptídios mutados de hev e uso dos mesmos para a contagem de anticorpos anti-hev
UA117493C2 (uk) Гібридна конструкція, що включає антигенсполучний фрагмент, специфічний до сироваткового альбуміну, й ефекторний компонент, та способи її одержання
MX2020010716A (es) Metodo para escindir de la fase solida peptidos unidos a una fase solida.
BR112018012055A2 (pt) substrato de transglutaminase (tg) recombinante, método in vitro para marcar uma proteína de interesse, composição farmacêutica ou de diagnóstico e kit de diagnóstico

Legal Events

Date Code Title Description
B350 Update of information on the portal [chapter 15.35 patent gazette]